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ABSTRACT 
Inherited bone marrow failure syndromes (IBMFS) are caused by mutations in genes involved in 
genomic stability. Although they may be recognized by the association of typical clinical features, 
variable penetrance and expressivity are common, and clinical diagnosis is often challenging. DNAJC21, 
which is involved in ribosome biogenesis, was recently linked to bone marrow failure. However, the 
specific phenotype and natural history remain to be defined. We correlate molecular data, phenotype, and 
clinical history of five unreported affected children and all individuals reported in the literature. 
All patients present features consistent with IBMFS: bone marrow failure, growth retardation, 
failure to thrive, developmental delay, recurrent infections, and skin, teeth or hair abnormalities. 
Additional features present in some individuals include retinal abnormalities, pancreatic insufficiency, 
liver cirrhosis, skeletal abnormalities, congenital hip dysplasia, joint hypermobility, and cryptorchidism. 
We suggest that DNAJC21-related diseases constitute a distinct IBMFS, with features 
overlapping Shwachman-Diamond syndrome and Dyskeratosis congenita, and additional characteristics 
that are specific to DNAJC21 mutations. The full phenotypic spectrum, natural history, and optimal 
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management will require more reports. Considering the aplastic anemia, the possible increased risk for 
leukemia, and the multisystemic features, we provide a checklist for clinical evaluation at diagnosis and 
regular follow-up. 
 
Key words: BMFS3, bone marrow failure syndrome, founder effect, genomic instability, genotype-
phenotype, management, natural history, ribosome, telomere  
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INTRODUCTION 
Inherited bone marrow failure syndromes (IBMFS) are characterized by cytopenia(s) due to 
impaired hematopoiesis, and to a varying degree, cancer predisposition. Most present with additional 
manifestations such as bone marrow failure, growth and developmental delay, osteopenia, and recurrent 
infections. Many IBMFS may be recognized by the association of distinct clinical or laboratory features: 
radial ray defects and increased chromosomal breaks in Fanconi anemia (FA); the presence of a classic 
triad (oral leukoplakia, nail dystrophy, and reticular hypopigmentation), associated with very short 
telomeres in Dyskeratosis congenita (DC); and chronic neutropenia, with exocrine pancreatic 
insufficiency and skeletal abnormalities in Shwachman-Diamond syndrome (SDS). However, variable 
penetrance and expressivity are common, making clinical diagnosis often challenging. So far, over 50 
genes have been associated with IBMFS.1 They are involved in genomic stability, DNA repair, telomere 
maintenance, and ribosome biogenesis. DNAJC21, which is required for 60S ribosomal subunit 
maturation, was recently linked to bone marrow failure in four individuals.2 Six other individuals with a 
biallelic mutation in this gene have been reported since.3,4 Full phenotypic spectrum, natural history, and 
management recommendations of this new entity remain to be defined. We describe molecular data, 
phenotype, and clinical history of five affected individuals from two families carrying the same biallelic 
mutation, compare molecular data and clinical information with all individuals reported in the literature, 
and suggest clinical management and follow-up that should be considered in all affected individuals. 
PATIENTS AND METHODS 
We describe five previously unreported children from two families of the same Canadian First-
Nation origin, as well as updated clinical information on three affected individuals from two previously 
reported families.2,4 All patients were evaluated in a clinical setting by multiple specialists, including a 
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geneticist. Approval for genomic studies was obtained from the Research Ethics Board of the CHU 
Sainte-Justine, and informed consent to publication of clinical information and photographs was obtained 
from parents or guardians. 
RESULTS 
Molecular data and clinical information are summarized in table 1 and detailed in table S1. 
Pedigrees are available in figure S1. All children presented features consistent with IBMFS: postnatal 
growth retardation, global developmental delay, skin, teeth and hair abnormalities, skeletal abnormalities, 
and bone marrow failure. The differential diagnosis included DC, SDS and Rothmund-Thomson 
syndrome, although they lacked the classic features of these disorders, and single gene sequencing failed 
to identify a mutation in any of the associated genes. Exome sequencing performed in patient 2 identified 
a homozygous variant in DNAJC21. This variant was then confirmed by Sanger sequencing in all 
affected. Available parents were heterozygous (figure S1). 
The identified mutation, NM_001012339.2:c.100A>G:p.Lys34Glu, deemed likely pathogenic 
(PM2, PM1, PP3, PP1),5 has since been reported in two siblings from a Canadian First-Nation tribe.3 
Including the patients in the current report, a total of 15 individuals carrying 9 different mutations, are 
now described with clinical information (summary in table 1, details in table S1). This includes seven 
patients, from three unrelated families, with the same missense mutation. All mutations are private, and 
all but one affected individual are homozygous. Four mutations are missense, within the J-domain of the 
protein, while the other five are truncating (figure 1A).  
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DISCUSSION 
Previous reports 
Bone marrow failure syndrome 3 (BMFS3, OMIM #617052) was first reported in four unrelated 
individuals with bone marrow failure and growth delay.2 Half (2/4) had dental and skin abnormalities, and 
one had retinal dystrophy. Since that original report, six individuals with biallelic mutations in DNAJC21 
have been reported.3,4 Four individuals reported by Dhanraj were clinically diagnosed with SDS. They 
presented bone marrow failure, skeletal abnormalities, pancreatic insufficiency and mild liver fatty 
changes or enzymes elevation. Three had short stature and cognitive or motor delay. Half (2/4) had skin 
abnormalities, and one had abnormal dentition. Although fulfilling the criteria for SDS, two had retinal 
dystrophy, and another had dysmorphic features, which is not typically found in SDS. Bluteau’s report 
included three individuals with DNAJC21 variants, out of a large bone marrow failure cohort (179 
individuals), therefore phenotypic information was limited. 
Current report 
We report the largest group of children with the same biallelic mutation in DNAJC21. They 
presented cytopenia(s), post-natal growth delay, failure to thrive (appendix S1), progressive 
microcephaly, motor or global development delay, mild dysmorphic features (figure S2), 
severe/precocious osteopenia, skeletal irregularities (figure 1B, and figure S3), congenital hip dysplasia, 
joint hypermobility, and skin or adnexa abnormalities (sparse fine hair, nail hypoplasia/dystrophy, 
microdontia or conical teeth, enamel abnormalities, carious teeth). Most (4/5) had recurrent and/or 
refractory infections in infancy, and both males had cryptorchidism. Three of the four tested had 
sensorineural hearing impairment, and two had retinal abnormalities. Short (between 1st and 10th 
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percentile) and/or very short (below 1st percentile) telomeres were observed in most affected individuals 
(figure S4).  
This contrasts with Tummala’s report, where all individuals had normal telomere length.2 This 
discrepancy could be the result of the measurement method used,6,7 disease severity, or each mutation’s 
pathogenic mechanism. Although telomere shortening has been described in other non-DC IBMFS, such 
as SDS and FA,8 it remained above the 1st percentile for most patients with SDS (12/14). In contrast, all 
patients tested in our cohort had at least one subpopulation at or below the 1st percentile, with most 
between 1st and 10th percentile, which is consistent with some level of telomere maintenance defect. 
Indeed, previous reports showed that defining normal telomere length as above the 1st percentile would 
miss children with telomeropathies,9 considering that up to one in seven are in the 1st to 10th percentile 
range.8 
In contrast to Dhanraj’s report,3 although two individuals in our cohort had pancreatic 
hyperechogenicity (patients 1 and 2), none demonstrated clear evidence of pancreatic insufficiency (table 
S1). Both had mild liver enzymes elevation, one developed cirrhosis by age 11, which is not typical of 
SDS. The siblings from Dhanraj’s report carrying the same mutation also had signs of liver disease, 
suggesting an association with this specific mutation. 
Finally, previously unpublished clinical information reveals that there may be additional recurrent 
features in this syndrome. Indeed, in addition to pancytopenia and growth delay, two siblings (Patient 7 
and 8, previously reported2,4) had motor delay and skin abnormalities (hypopigmented skin, 
hyperkeratosis or eczema). One also had retinal dystrophy, microdontia, abnormal teeth morphology, 
osteoporosis, hip dislocation, and growth hormone deficiency, while her brother had microcephaly and a 
cardiac malformation. Neither had evidence of pancreatic insufficiency. 
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Therefore, we suggest BMFS3 constitutes a condition distinct from SDS and DC, with features 
overlapping both syndromes, and additional characteristics that are specific to DNAJC21 mutations 
(figure 1C).  It would be premature to restrict DNAJC21’s role to ribosome biogenesis, considering there 
are few human studies on this RNA-binding protein. Although no data supporting a role in telomere 
maintenance is available at this time, many features observed in affected individuals are not in the usual 
SDS spectrum, but rather evocative of dyskeratosis congenita, a telomeropathy. One of the associated 
gene, DKC1, is one example of a protein involved both in ribosome maturation and telomere 
maintenance.10 The phenotypic variations observed in the individuals reported so far could result from 
differential pathogenic mechanisms or variable expressivity. It is plausible that missense mutations within 
the J domain lead to gain-of-function interfering with other cellular processes, while truncating mutations 
are limited to 60S subunit maturation impairment. It is also probable that individual genetic background 
influences the expressed phenotype, considering DNAJC21’s involvement in crucial cellular processes. 
Based on the clinical features found in affected individuals, we suggest a thorough clinical 
evaluation at diagnosis and regular follow-up (table 2). 
Natural history 
All children in our cohort demonstrated various degree of bone marrow failure, but none of them 
required bone marrow transplant (BMT) nor developed leukemia (details in appendix S2). Moreover, 
although our cohort is small, all patients followed at our center showed improvement in their cell counts 
with age, except for lymphocytes (figure S5), and none required transfusions past 5 years old. 
It is worth mentioning that an acquired 17p13 deletion encompassing TP53 appeared in the 
hypocellular bone marrow of a 5 ½ year-old boy (patient 3). There is no dysplasia in his bone marrow, 
and the significance of this cytogenetic abnormality remains unknown (details in appendix S2). This 
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deletion may represent an initial event that could lead to tumorigenesis, or a rescue mechanism that could 
help recover hematopoiesis, or both.  
We report updated clinical information on three previously reported patients (details in table S1, 
pedigrees in figure S1). To our knowledge, only one individual with a DNAJC21 mutation developed 
leukemia (patient 6). He died from transplant-related morbidity, after a mismatched BMT for acute 
megakaryoblastic leukemia. Another 2-year-old male (patient 8) is currently stable and no longer 
transfusion-dependent, 9 months after an uncomplicated matched BMT performed for severe 
pancytopenia (details in table S1). His sister (patient 7) required transfusions in infancy, but her counts 
have stabilized since. Two siblings reported by Dhanraj died: one from sepsis, and one from EBV-
associated lymphoproliferative disorder shortly after BMT. Neither had leukemia, but one had a bone 
marrow karyotype abnormality: der(15)t(1;15)(q12;p11). 
Biallelic mutations in DNAJC21 cause a distinct IBMFS, with some clinical overlap with SDS 
and DC, and additional features such as retinal abnormalities, liver cirrhosis, congenital hip dysplasia, 
joint hypermobility, and cryptorchidism. More reports are needed to understand the full phenotypic 
spectrum and long-term evolution of affected individuals, and establish optimal management, including 
BMT indications and protocol. Aplastic anemia, and a possible increased risk for leukemia warrants 
regular hematological follow-up, and multidisciplinary care to address all other potential medical issues.  
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Table 1. Molecular data and summary of clinical features found in all reported individuals with biallelic mutations in DNAJC21. 
 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6† Patient 7‡ Patient 8§ Tummala 
Subject 4 
Dhanraj 
Patient 1 
Dhanraj 
Patient 2 
Dhanraj 
Patient 3 
Dhanraj 
Patient 4 
Bluteau 
Patient 54¶ 
Bluteau 
Patient 114 
Mutation (cDNA) 100A>G 100A>G 100A>G 100A>G 100A>G 94C>G 983+1G>T 983+1G>T 793G>T 520C>T 100A>G 100A>G 438-
?_894+?del 
517C>T 14A>G/114
3_1146del 
Protein change Lys34Glu Lys34Glu Lys34Glu Lys34Glu Lys34Glu Pro32Ala Gly299Ala 
fs*2 
Gly299Ala 
fs*2 
Glu265* Gln174* Lys34Glu Lys34Glu Val148Lys 
fs*30 
Arg173* Tyr5Cys/ 
Lys381fs 
Mutation feature Missense Missense Missense Missense Missense Missense FS + stop 
gain 
FS + stop 
gain 
Stop gain Stop gain Missense Missense FS + stop 
gain 
Stop gain Missense / 
In-frame 
deletion 
Protein domain J domain J domain J domain J domain J domain J domain Interdomain Interdomain Coiled coil Interdomain J domain J domain Interdomain Interdomain J domain / 
Interdomain 
Gender M F M F F M F M F F M M M F F 
Age (initial/last 
evaluation) 
5m/ 
12y1m 
8m/ 
9y10m 
2y6m/ 
5y7m 
13m/ 
5y1m 
2m/14m 12y/uk 6y/ 
14y6m 
6m/2y 6y/uk 2y6m/14y Birth/18m Birth/7y4m Birth/11y 3y/uk 14m/uk 
Growth delay ± FTT + + + + + + + + + + - + + + uk 
Pancytopenia/BMF + + + + + + + + + + + + + + uk 
Dysmorphic facial 
features 
+  + + + uk - - uk + - - - uk uk 
Neurological features + + + + - uk + + uk + - + + uk + 
Microcephaly + - + + - - - + - uk uk uk uk + uk 
Eye abnormalities + + + - uk uk + - uk + - - + uk uk 
Skeletal abnormalities + + + + + uk + uk uk + + + + uk uk 
Skin & adnexa 
abnormalities 
+ + + + + + + + uk + - - + uk uk 
Recurrent/severe 
infections 
+ + + + - uk - - uk + + - - uk uk 
Digestive system 
abnormalities 
+ + - - - uk + - + + + + + uk uk 
Genitourinary 
abnormalities 
+ - + + - uk - - uk uk - - uk uk uk 
Other Fetal 
cystic 
hygroma 
    GH 
deficiency. 
Deceased 
post-BMT 
(TRM) 
GH 
deficiency 
Bicuspid 
aortic valve, 
ventricular 
septal defect 
  Deceased 
pre-BMT 
(sepsis) 
Deceased 
post-BMT 
(EBV-
associated 
PTLD) 
   
Short telomeres + + + + + - ± - - - uk uk uk - uk 
Bone marrow 
cytogenetic 
abnormality 
- - del(17p13.1) 
(63% of 
cells at 
5y6m) 
del(20q) 
(9.7% of 
cells at 
17m) 
- uk uk uk uk - - der(15) 
t(1;15)(q12;
p11)  
(8m-7y) 
- 47-51,XX, 
+X,+8,+13,+
21,+22 
uk 
Malignancy - - - - - AML-M7 - - - - - - - - - 
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BMT - - - - - + - + uk - - + + uk uk 
Alive + + + + + - + + uk + - - + uk uk 
F, female; M, male; m, months; y, years; +, present; -, not present; uk, unknown. 
BMF, bone marrow failure; BMT, bone marrow transplant; FS, frameshift; FTT, failure to thrive; GH, growth hormone; PTLD, post-transplant lymphoproliferative disorder; TRM, transplant-related mortality. 
Previously reported patients: † Tummala et al. (subject 3); ‡ Tummala et al. (subject 2); § Bluteau et al. (Patient 91); ¶ Tummala et al. (subject 1).
This article is protected by copyright. All rights reserved.
  
Table 2. Recommended management. 
 
 Investigation/intervention At Diagnosis At Follow-up 
Genetics Gene testing (familial mutation if known, or sequencing; patient, 
family member if HSCT donor) 
Yes If not done at diagnosis 
 Genetic counseling ± molecular testing (adult carrier) - Yes 
 Telomere length testing (patient, family member if HSCT donor) Yes - 
Hematology Complete blood count, reticulocytes Yes Every 3-4 months or as clinically indicated 
 Bone marrow aspirate & biopsy + microarray or karyotype & 
FISH panel 
Yes Every 1-3 years or as clinically indicated 
 Iron, vitamin B12, folate Yes As clinically indicated 
 Fetal hemoglobin Yes - 
 HLA typing (affected, siblings and parents) As clinically 
indicated 
As clinically indicated 
Neurology Head circumference measurement Yes Yearly 
 Cerebral imaging (MRI) - As clinically indicated 
 Neurodevelopmental evaluation Yes Every 6 months until 6 years, then 
screening at 11-13 years old, or as 
clinically indicated 
 Physiotherapy, occupational therapy, speech therapy - As clinically indicated 
Ophthalmology Standard eye exam Yes Yearly 
 Electroretinography Yes Every 2 years 
Audiology Audiogram or auditory brain-stem evoked response testing Yes As clinically indicated 
Growth, skeletal Weight & height Yes Yearly 
 Hip dysplasia screening ± orthopedics referral Yes - 
 Bone mineral density measurement Yes Every 2 years, or as clinically indicated 
 Skeletal survey (metaphyseal dysplasia, compression fractures) Yes Before age 5, then as clinically indicated 
 Bone age - As clinically indicated 
 Parathyroid hormone level Yes - 
 Calcium (ionized), phosphorus Yes Every 2 years 
Endocrine IGF-1 or GH stimulation test (GH deficiency) Yes As clinically indicated 
 Thyroid stimulating hormone Yes As clinically indicated 
Immunologic Lymphocyte phenotype Yes As clinically indicated 
 IgG, IgM, IgA levels Yes - 
 Post vaccination serologies - As clinically indicated 
 Antibiotic prophylaxis - As clinically indicated 
Gastrointestinal & 
hepatic 
Pancreatic function testing: fecal elastase, trypsinogen (d 3y) or 
pancreatic isoamylase (e  3y) 
Yes Yearly until 5 years old, then as clinically 
indicated 
 Liver enzymes, albumin, bilirubin, prothrombin time Yes Yearly or as clinically indicated 
 Nutritional status: lipid panel, vitamins A, D, E Yes Yearly 
 Abdominal ultrasound (pancreas & liver) Yes Every 2 years until 6 years old, then as 
clinically indicated 
 Dental care (caries, gingivitis) Yes Every 6-12 months 
 Esophagram, endoscopy - As clinically indicated 
Dermatologic Skin & nail examination, cancer surveillance Yes Yearly 
 Eczema treatment - As clinically indicated 
Other Pelvic ultrasound (kidney, testicles) Yes - 
 Echocardiogram Yes - 
 Pulmonary function tests, pulse oximetry, diffusion capacity of 
the lung for carbon monoxide testing, six-minute walk test 
- As clinically indicated 
 Chest computed tomography (pulmonary fibrosis) - As clinically indicated 
 Avoid: prolonged use of cytokines and hematopoietic growth 
factors, unnecessary radiograph studies 
  
GH, growth hormone; HSCT, hematopoietic stem cell transplant 
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FIGURE LEGEND 
Figure 1. Biallelic mutations in DNAJC21 cause features overlapping with Dyskeratosis congenita 
and Shwachman-Diamond syndrome.  
(A) Number and mutations types reported, with corresponding position in DNAJC21 protein and its 
domains. The missense homozygous mutations found in our cohort (p.K34E) and in subject 3 from 
Tummala’s cohort (p.P32A) are located in the J-domain. Other reported homozygous mutations are 
outside of the J-domain. (B) Representative X-rays of children in this report showing skeletal anomalies. 
Pt 3 (5y): marked copper beaten aspect of the skull (asterisk), flattened sella turcica (arrow) and 
brachycephaly. Pt 4 (5y): bilateral irregular and cupped metaphysis of distal metacarpals (arrow). Pt 1 
(3y): bilateral metaphysis flaring of distal femur and proximal tibia (arrows), and mild lateral bowing of 
tibia and fibula (asterisk). Pt 1 (10y): bilateral acetabular dysplasia (asterisk), with sclerotic, irregular and 
flattened femoral head, coxa magna and breva (bracket), and “sagging rope sign” over femoral 
metaphysis (arrow). Pt 5 (14mo): bilateral growth lines in distal metaphysis of radius and ulna (arrows). 
Pt 5 (14mo): bilateral growth lines in metaphysis of distal femur and proximal tibia (arrows). (C) Venn 
diagram of clinical features found in at least two individuals with DNAJC21 biallelic mutations, 
compared with features typically found in Dyskeratosis congenita and Shwachman-Diamond syndrome. 
(BMF, bone marrow failure; DD, developmental delay; IUGR, intra-uterine growth retardation; mo, 
months old; Pt, patient; y, years old). 
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